(external) researcher Erasmus School of Health Policy & Management Health Technology Assessment (HTA)
- Location
- Burg. Oudlaan 50, Rotterdam
- kuppen@eshpm.eur.nl
More information
‹ Back to overview
Profile
- M.C.P. Kuppen, H.M. Westgeest, A.J.M. Van den Eertwegh, J. Coenen, R.J.A. van Moorselaar, P. Berg, M.M. Geenen, N. Mehra, M.P. Hendriks, M.I. Lampe, A.C.M. van de Luijtgaarden, F.P.J. Peters, T.A. Roeleveld, T. Smilde, R. de Wit, I. van Oort, W. Gerritsen & C.A. de Groot (2020). Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. Clinical Genitourinary Cancer, 18 (3), E233-E253. doi: 10.1016/j.clgc.2019.11.015
- S. Schmid, A. Omlin, C. Higano, C. Sweeney, N.M. Chanza, N. Mehra, M.C.P. Kuppen, H. Beltran, V. Condeduca, D.V.P. de Almeida, F.C. Maluf, W.K. Oh, C.K. Tsao, O. Sartor, E. Ledet, G. Di Lorenzo, S.M. Yip, K.N. Chi, D. Bianchini, U. De Giorgi, A.R. Hansen, T.M. Beer, L. Pernelle, R. Morales-Barrera, M. Tucci, E. Castro, K. Karalis, A. Bergman, M.L. Le, U. Zurrer-Hardi, C. Pezaro, H. Suzuki, A. Zivi, D. Klingbiel, S. Schar & S. Gillessen (2020). Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. Jama Network Open, 3 (10). doi: 10.1001/jamanetworkopen.2020.21692
- P.H.J. Slootbeek, M.L. Duizer, M.J. Doelen, I.S.H. Kloots, M.C.P. Kuppen, H.M. Westgeest, C.A. de Uyl-de Groot, S. Pamidimarri Naga, M.J.L. Ligtenberg & I. van Oort (2020). Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. International Journal of Cancer, 148 (2), 385-395. doi: 10.1002/ijc.33306
- M.C.P. Kuppen & H.M. Westgeest (2019). Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Oncology. doi: 10.1016/j.euo.2019.09.005.
- H.M. Westgeest, M.C.P. Kuppen, A.J.M. Van den Eertwegh, R. de Wit, J. Coenen, H. van den Berg, N. Mehra, I. van Oort, L. Fossion, M.P. Hendriks, H. Bloemendal, A.C.M. van de Luijtgaarden, D. Huinink, A.C.M. van den Bergh, J.G. Bosch, M.B. Polee, N. Weijl, A. Bergman, C.A. de Groot & W. Gerritsen (2019). Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. Clinical Genitourinary Cancer, 17 (5), E946-E956. doi: 10.1016/j.clgc.2019.05.018
Module Knowledge
- Title
- Module Knowledge
- Year
- 2020
- Year level
- bachelor 1
(external) researcher
- University
- Erasmus University Rotterdam
- School
- Erasmus School of Health Policy & Management
- Department
- Health Technology Assessment (HTA)
- Country
- The Netherlands